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Abstract
Background: WT1 is a tumor suppressor gene responsible for Wilms' tumor. WT1 reactivity is
limited to ovarian serous carcinomas. Recent studies have shown that WT1 plays an important role
in the progression of disease and indicates a poorer prognosis of human malignancies such as acute
myeloid leukemia and breast cancer. The aims of this study were to determine the survival and
recurrence-free survival of women with advanced serous epithelial ovarian carcinoma in relation
to WT1 gene expression.
Methods: The study accrued women over an 18-year period, from 1987–2004. During the study
period, 163 patients were diagnosed with advanced serous epithelial ovarian carcinoma and had
undergone complete post-operative chemotherapy, but the final study group comprised 99
patients. The records of these women were reviewed and the paraffin-embedded tissue of these
women stained with WT1 immunostaining. Survival analysis was performed using Kaplan-Meier and
Cox regression methods.
Results: Fifty patients showed WT1 staining and forty-nine did not. Five-year survival of non-
staining and staining groups were 39.4% and 10.7% (p < 0.00005); five-year recurrence-free survival
of these groups were 29.8% and ≤ 7.5% (p < 0.00005), respectively. For survival the HR of WT1
staining, adjusted for residual tumor and chemotherapy response, was 1.98 (95% CI 1.28–3.79), and
for recurrence-free survival the HR was 3.36 (95% CI 1.60–7.03). The HR for recurrence-free
survival was not confounded by any other variables.
Conclusion: This study suggests that expression of WT1 gene may be indicative of an unfavorable
prognosis in patients with advanced serous epithelial ovarian carcinoma.
Background
Ovarian cancer is one of the leading problems in gyneco-
logic malignancy in females worldwide. In Thailand, ovar-
ian cancer is the sixth most common cancer among
females, with approximately 1,655 new cases per year [1].
Although several histologic types of epithelial ovarian
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cancer exist, approximately 60% are of the serous epithe-
lial type [2]. Due to their nonspecific initial symptoms,
70% of patients have widespread metastatic disease at the
time of diagnosis [3]. Survival rate is generally low.
Despite advances in evaluation and treatment, the sur-
vival rate for all stage of ovarian cancer has remained con-
stant over the past 30 years [4]. Parameters such as
International Federation of Gynecology and Obstetrics
(FIGO) stage at diagnosis, histologic grade, cell type, and
amount of residual disease after first surgery, represent the
most important factors to date for distinguishing between
those patients who will have favorable and unfavorable
clinical outcomes. In addition, more recent various
immunohistochemical studies of ovarian cancer have sug-
gested that expression of particular markers may help in
predicting outcome, and therefore guide therapeutic
choices [2,4-8].
Wilms' tumor is a kidney malignancy of childhood that is
thought to arise as a result of inactivation of both alles of
the Wilms' tumor gene (WT1) located at chromosome
11p13 [9,10]. WT1 is a tumor suppressor gene responsible
for Wilms' tumor. In normal human tissue, WT1 is
restricted to kidney, testis, ovary, spleen, hematopoietic
precursors, and the meseothelial cell lining of visceral
organs [11].
Recent studies have shown that WT1 plays an important
role in the progression of disease and prognosis of human
malignancies [12-15]. Bergmann et al. reported that high
expression of WT1 mRNA is associated with a worse long-
term prognosis of acute myeloid leukemias patients [13].
Similarity, Miyoshi et al. reported that measurement of
WT1 mRNA levels in tumor tissues might be useful as a
new prognostic factor in breast cancer patients [15]. In
epithelial ovarian tumors, WT1 expression has been
detected [16]. WT1 reactivity is limited to ovarian serous
carcinomas, and is not found in mucinous carcinomas
[18,19]. However, until now, there are no reports of asso-
ciation between survival and the WT1 gene. The aim of
this study, therefore, was to determine the survival and
recurrence-free survival of women with advanced serous
epithelial ovarian carcinoma in relation to WT1 gene
expression. In the present study, expression of WT1 was
examined by immunohistochemistry.
Methods
Patients
This study was approved by the Research Committee of
the Faculty of Medicine, Prince of Songkla University. The
medical records of all women diagnosed with FIGO stage
III and IV serous ovarian carcinoma in Department of
Obstetrics and Gynecology, Songklanagarind Hospital,
from January 1987 to December 2004, were retrospec-
tively reviewed. The clinicopathology details such as age,
parity, chief complaint, FIGO stage, histologic grade,
residual tumor, and chemotherapy response were
assessed. The standard operation procedures were total
abdominal hysterectomy, bilateral adnexectomy, omen-
tectomy, lymph node sampling, and peritoneal washing.
After tumor debulking these women received adjuvant
chemotherapy, platinum analog and cyclophosphamide,
for six cycles. For women who underwent only tumor
biopsy at the first operation, chemotherapy was given for
three cycles, then interval debulking of the tumor per-
formed in the same fashion, followed by an additional
three cycles of chemotherapy. The tissues from these
patients were used for the study group. Fully informed
consent was obtained from all patients prior to surgery,
and tumor samples were collected during surgery. The
response of the women to chemotherapy was evaluated
use WHO criteria [20]. All deaths were registered by the
Medical Statistic Unit and Cancer Registry Unit of Song-
klanagarind Hospital, and the Department of Provincial
Administration, Ministry of Interior, according to death
certificates issued by a physician stating the cause of
death. The status of all living and/or lost to follow-up
patients was confirmed directly by telephoning or mailing
and by checking the census records from the Hatyai City
Municipality.
The H&E sections show a solid area of tumor which consists  of cuboidal tumor cells with eosinophilic cytoplasm and  vesicular nuclei, with prominent nucleoli Figure 1
The H&E sections show a solid area of tumor which consists 
of cuboidal tumor cells with eosinophilic cytoplasm and 
vesicular nuclei, with prominent nucleoli. Mitotic figures are 
frequently observed (a). The immunohistochemical study of 
the same patient shows faint nuclei staining (intensity 1+) for 
WT1 protein in the most of tumor cells (b). The immunohis-
tochemical studies show strong immunoreactivity in the 
nuclei in the majority of tumor cells (c: intensity 2+, d: inten-
sity 3+)BMC Cancer 2006, 6:90 http://www.biomedcentral.com/1471-2407/6/90
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Table 1: Characteristic of 99 advanced serous epithelial ovarian carcinoma patients
Characteristic Number of cases(%)
1. Age (years)
≤ 20 2 (2.0)
20–30 3 (3.0)
31–40 3 (3.0)
41–50 25 (25.3)
51–60 36 (36.4)
61–70 23 (23.2)
71–80 7 (7.1)
2. Parity
0 21 (21.2)
1 11 (11.1)
2 16 (16.2)
3 10 (10.1)
4 12 (12.1)
5 10 (10.1)
≥6 19 (19.2)
3. Chief complain
Abdominal distension 54 (54.5)
Pelvic mass 33 (33.3)
Bleeding per vagina 4 (4.0)
Weight loss 1 (1.0)
Pelvic pain 7 (7.1)
4. FIGO Staging
III 85 (85.9)
IV 14 (14.1)
5. Histologic grade
1 60 (60.6)
2 24 (24.2)
3 15 (15.2)
6. Residual tumor (cm)
None 8 (8.1)
>0–≤1 4 (4.0)
>1–≤2 50 (50.5)
>2 13 (13.2)
No data 24 (24.2)
7. Percent staining
0 49 (49.5)
1–25 13 (13.1)
26–50 16 (16.2)
51–75 12 (12.1)
≥76 9 (9.1)
8. Intensity
0 (no staining) 49 (49.5)
1+ 29 (29.3)
2+ 19 (19.2)
3+ 2 (2.0)
9. Chemotherapy response
Complete 62 (62.6)
Partial 8 (8.1)
Stable 8 (8.1)
Progressive 2 (21.2)
10. Recurrence
Yes 54 (77.1)
No 16 (22.9)
11. Status at last follow-up
DWD 69 (69.7)
DWID 4 (4.0)
AWD 3 (3.0)
ANED 7 (7.1)
Loss follow-up 16 (16.2)
DWD = death of disease, DWND = death with intercurrent disease, AWD = alive with Disease, ANED = alive with no evidence of diseaseBMC Cancer 2006, 6:90 http://www.biomedcentral.com/1471-2407/6/90
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Immunohistochemical staining
The hematoxylin and eosin stained histologic slides from
each patient were reviewed and the corresponding paraf-
fin-embedded tissue blocks selected by one pathologist of
the Department of Pathology, Prince of Songkla Univer-
sity. Sections (5µm) from archival formalin-embedded
tissue blocks were mounted on the salinized slides, and
baked overnight at 60°C. They were then deparaffinized
in xylene, rehydrated in a decreasing ethanol series and
rinsed in phosphate buffered saline (PBS), pH 7.4. Endo-
geneous peroxidase was blocked using 0.3% H2O2 in PBS
for 5 min. The tissue slides were then subjected to antigen
retrieval by microwave followed by blocking with 10%
normal horse serum. The tissue slides were then incubated
with monoclonal mouse antibody against WT1 (1:100)
overnight at 4°C followed by addition of biotinylated
rabbit anti-mouse IgG secondary antibody (Vecta staining
kit) and then avidin-biotin-peroxidase complex (Vecta
staining kit) according to the manufacturer's protocol.
Visualization of the immunoreaction was achieved using
diaminobenzidine tetrahydrochloride and hydrogen per-
oxide (0.03% in 50 mM Tris-HCl, pH 7.6) for 10 min. Sec-
tions were rinsed in tap water, counterstained with
hematoxylin, dehydrated through graded alcohol, cleared
in xylene, and mounted using DPX. Positive nuclear
immunostaining in Sertoli cells had to be demonstrated
in the immunohistochemical study for the quality control
purpose.
Determination of staining
The immunostained slides were examined using an Olym-
pus light microscope equipped with a grid eyepiece. The
sections were evaluated by one pathologist. The area of
tumor cells was screened and a minimum of 1,000 tumor
cells were counted for each slide, excluding foci of inflam-
mation and necrosis. The number of tumour cells with
nuclear staining was recorded and reported as percentage
staining and the intensity classified as 0, 1+, 2+, 3+ (Fig.
1) [16].
Statistical analysis
Survival time was calculated from the date of starting
treatment to the date of death or censoring at the last fol-
lowed-up. Similarly, recurrence-free survival was calcu-
lated from the date of starting treatment to the date of
recurrence or death or last follow-up, whichever occurred
Table 2: Relationship of WT1 staining with other   clinicopathological variables of 99 advanced serous epithelial ovarian carcinoma   
patients
Characteristic No staining (N = 49) Staining (N = 50) p-value
1. FIGO Staging 0.967
III 42 (85.7) 43 (86.0)
IV 7 (14.3) 7 (14.0)
2. Histologic grade 0.610
1 32 (65.3) 28 (56.0)
2 10 (20.4) 14 (28.0)
3 7 (14.3) 8 (16.0)
3. Residual tumor (cm) 0.009
None 8 (16.3) 5 (10.0)
>0–≤1 2 (4.1) 6 (12.0)
>1–≤2 3 (6.1) 1 (2.0)
>2 18 (36.7) 32 (64.0)
No data 18 (36.7) 6 (12.0)
4. Chemotherapy response 0.036
Complete 37 (75.5) 25 (50.0)
Partial 3 (6.1) 5 (10.0)
Stable disease 4 (8.2) 4 (8.0)
Progressive disease 5 (10.2) 16 (32.0)
Kaplan-Meier overall survival profile of the 99 advanced  serous epithelial ovarian carcinoma women Figure 2
Kaplan-Meier overall survival profile of the 99 advanced 
serous epithelial ovarian carcinoma womenBMC Cancer 2006, 6:90 http://www.biomedcentral.com/1471-2407/6/90
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first, confining the analysis to those patients who showed
a complete response to chemotherapy.
Patients were divided into two groups, those with percent-
age staining ≥ median and those with percentage staining
< median. Survival profiles of the entire groups were
examined using Kaplan-Meier plots. Multivariate Cox pro-
portional hazards regression was used to examine the
crude and adjusted hazard ratios for WT1 staining and to
identify these variables with an independent association
with survival and with recurrence-free survival. For multi-
variate modeling, all variables were initially included and
the least significant variable was removed in a stepwise
process until all remaining variables showed a statistically
significant contribution (P < 0.05) to the fit of the model.
WT1 staining was retained irrespective of its statistical sig-
nificance. Statistical significance of each variable was
assessed using the change in log-likelihood of successive
models.
Power of the study
The study accrued women over an 18-year period, from
1987–2004. During the study period, 163 patients were
diagnosed with advanced serous epithelial ovarian carci-
noma and had undergone complete post-operative chem-
otherapy. Among these, 36 had no medical records and
another 28 had no tumour specimens. Thus, the final
Kaplan-Meier recurrence-free survival profile of the 62  advanced serous epithelial ovarian carcinoma women with  complete response to chemotherapy Figure 3
Kaplan-Meier recurrence-free survival profile of the 62 
advanced serous epithelial ovarian carcinoma women with 
complete response to chemotherapy
Table 3: Univariate analysis of potential prognostic factors for survival of 99 advanced serous epithelial ovarian carcinoma patients
Characteristic Hazard ratio 95%CI p-value
1. FIGO Staging
III 1 - 0.6188
IV 1.21 0.58–2.56
2. Histologic grade
1 1 - 0.6569
21 . 3 10 . 7 4 – 2 . 3 0
31 . 1 30 . 8 6 – 2 . 2 6
3. Residual tumor (cm)
None 1 - 0.3046
>0–≤1 2.24 0.79–6.37
>1–≤2 0.99 0.21–4.62
>2 1.75 0.87–3.66
4. Chemotherapy response
Complete 1 - 0.0001
Partial 0.99 0.39–2.53
Stable 3.47 1.52–7.91
Progressive 3.80 2.12–6.82
5. WT1 staining
No 1 - 0.0001
Yes 2.79 1.70–4.57
6. Percent staining
0 1 - 0.0008
1–25 4.05 1.89–8.70
26–50 2.50 1.30–4.82
51–75 1.97 0.86–4.54
≥76 3.58 1.61–7.96
7. Intensity
0 1 - 0.0002
1+ 2.56 1.47–4.48
2+ or 3+ 3.23 1.70–6.14BMC Cancer 2006, 6:90 http://www.biomedcentral.com/1471-2407/6/90
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study group comprised 99 patients. While there are no
previous studies of WT1 gene and survival times of ovar-
ian cancer, the 5-year overall survival of advanced epithe-
lial ovarian carcinoma has been reported to be between
11 and 41% [17]. For the purposes of power calculation,
we assumed a 5-year overall survival of about 23%, corre-
sponding to a rate of death of 0.293 year-1, based on an
assumed exponential survival profile. We planned to
compare the survival of patients showing WT1 staining
percentage ≥ median with that of patients have < median
percentage staining. Assuming the rate to be equally
increased and decreased among the ≥ median group with
and < median group, then to detect a difference in 5-year
survival of 14% (death rate = 0.393 year-1) and 36%
(death rate = 0.204 year-1) respectively in the two groups
as significant at a 2-sided alpha of 0.05 with a power of
80% required 99 subjects.
Results
Mean age at diagnosis was 54.53 years (range 18–80
years). The most prominent presenting symptom were
abdominal distension (54.5%) and pelvic mass (33.3%).
M o s t  o f  t h e  p a t i e n t s  w e r e  i n  F I G O  s u r g i c a l  s t a g e  I I I
(85.9%). Only 50 patients (50.5%) were reactive for WT1.
The distribution by WT1 staining intensity 1+, 2+, 3+ was
29.3%, 19.2%, 2.0%, respectively, and almost exactly half
had no staining. Thus the patients were divided into non-
staining and staining groups. The clinical outcome and
other characteristics of the patients are shown in Table 1.
The relationships of clinicopathologic variables and WT1
expression are shown in Table 2. No significant associa-
tion between WT1 group and FIGO stage, histologic grade
or residual tumor was found. Only chemotherapy
response and residual tumor showed significant differ-
ence between WT1 staining and no WT1 staining patients.
The 5-year survival of non-WT1 staining patients was
39.4% (95% CI 25.1 – 53.4) compared with 10.7% (95%
CI 3.2 – 23.6) in the WT1-statining patients (p < 0.00005)
(Fig. 2). In univariate Cox proportional hazards models,
survival was found to be statistically significantly poorer
in patients who did not respond to chemotherapy and in
patients whose tissue showed WT1 staining. There was no
evidence, however, that the hazard was increased with
increasing percentage or increasing intensity of staining
(Table 3). Both WT1 staining and chemotherapy response
remained significant predictors of survival in a multivari-
ate regression model. Stable and progressive disease were
associated with hazard ratios of 2.29 (95% CI 0.80–6.13)
and 2.93 (95% CI 1.53–5.62) compared with a complete
response to chemotherapy, and WT1 staining with a haz-
ard ratio of 1.98 (95% CI 1.28–3.79; p = 0.0138) (Table
4).
Among patients who showed a complete response to
chemotherapy, the 5-year recurrence-free survival of those
who showed no WT1 staining was 29.8 percent (95% CI
15.6–45.4) compared with ≤ 7.5% (95% CI 0.6–27.2) in
the WT1 statining patients (p < 0.00005) (Fig. 3). Cox
proportional hazards modeling revealed WT1 staining to
be the only statistically significantly predictor of recur-
rence-free survival, either in univariate models (Table 5)
Table 4: Multivariate analysis of potential prognostic factors for overall survival of 99 advanced serous epithelial ovarian carcinoma 
patients
Characteristic Hazard ratio 95%CI p-value
1. FIGO staging
III 1 - 0.4602
IV 1.47 0.54 – 3.97
2. Histologic grade
1 1 - 0.9456
20 . 9 60 . 5 0  –  1 . 8 4
31 . 1 10 . 5 0  –  2 . 4 6
3. Residual tumor (cm)
None 1 - 0.3522
>0 – 1 2.63 0.86 – 1.84
>1 – 2 0.74 0.13 – 4.11
>2 1.28 0.59 – 2.79
4. Chemotherapy response
Complete 1 - 0.0038
Partial 0.61 0.22 – 1.72
Stable 2.29 0.86 – 6.13
Progressive 2.93 1.53 – 5.62
5. WT1 staining
No 1 - 0.0138
Yes 1.98 1.28 – 3.79BMC Cancer 2006, 6:90 http://www.biomedcentral.com/1471-2407/6/90
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or after testing in a multivariate setting. The hazard ratio
was 3.36 (95% CI 1.60–7.03; p = 0.0017) (Table 6). As
with overall survival, there was no evidence that the haz-
ard was increased with increasing percentage or increasing
intensity of staining.
Discussion
In the present study, we could demonstrate the immuno-
histochemical expression of WT1 gene in advanced serous
ovarian carcinomas. There are many reports showing that
in epithelial ovarian tumors, serous tumors generally
revealed a high WT1 gene expression [16,18,19]. We
found that about 50% of advanced serous ovarian carci-
noma patients were reactive for WT1. Analogous findings
have been recently reported by Schorge et al [21]. Con-
versely, Goldstein et al. reported that 93% of serous ovar-
ian carcinoma patients were reactive for WT1 [18]. The
reasons for these discrepancies are unclear. However this
finding is unlikely to be due to the technical issue as we
performed the strict quality control for the immunohisto-
chemical study.
The molecular mechanism underlying the difference in
the prevalence of WT1 geneexpression between our study
and previous published data was not clear at the moment.
Due to the fact that WT1 gene has been shown to be tran-
scriptionally regulated by some upstream transcriptional
factors like Sp1, PAX2, PAX8 and PEA3, it is worthwhile to
further analyze the expression status of these upstream
molecules in ovarian cancer specimens obtained from this
population [22-26]. Moreover, as the biological function
of WT1 has been shown to be influenced by other interac-
tive proteins like p53 and par-4, the expression status of
thesegenes should be evaluated in order to better define
the prognostic value of WT1 gene expression [27,28]. This
finding may reflect the different oncogenic pathway in
this cancer in Thai population.
Since the report by Inoue et al. in 1994, it has become
clear that WT1 gene expression is a new prognostic factor
and new marker for the detection of minimal residual dis-
ease in acute leukemia [12]. The prognostic value of WT1
gene expression was corroborated by later studies in
patients with acute leukemia, nephroblastoma and breast
cancer [13-15,29,30].
In ovarian cancer, Shimizu et al. suggested that WT1 gene
may be related to cell differentiation, and to the histologic
subtypes of epithelial ovarian carcinomas [16]. Goldstein
et al. reported that WT1 expression could be used as anti-
body to distinguish pancreatocobiliary and some ovarian
epithelial neoplasms [18]. However, the relationship of
WT1 expression in serous ovarian carcinoma with adverse
outcome had not previously been reported. We found that
WT1 gene expression and failure to respond to chemo-
therapy were significantly associated with overall survival
and only WT1 gene expression to be significantly associ-
ated with recurrence-free survival. This is the first report
Table 5: Univariate analysis of potential prognostic factors for recurrence free survival among 62 advanced serous epithelial ovarian 
carcinoma patients showing complete response to chemotherapy
Characteristic Hazard ratio 95%CI p-value
1. FIGO Staging
III 1 - 0.5904
IV 1.24 0.57–2.70
2. Histologic grade
1 1 - 0.9316
20 . 8 70 . 4 0 – 1 . 8 5
30 . 9 80 . 4 5 – 2 . 1 4
3. Residual tumor (cm)
None 1 - 0.3123
>0–≤1 2.54 0.65–9.95
>1–≤2 0.40 0.05–3.19
>2 1.35 0.59–3.08
4. WT1 staining
No 1 - 0.0001
Yes 3.64 1.93–6.84
5. Percent staining
0 1 - 0.0002
1–50 5.22 2.51–10.82
51–100 2.51 1.10–5.75
6. Intensity
0 1 - 0.0002
1+ 3.11 1.55–6.24
2+ or 3+ 6.28 2.40–16.41BMC Cancer 2006, 6:90 http://www.biomedcentral.com/1471-2407/6/90
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that demonstrates the prognostic significance of WT1
gene expression in serous ovarian carcinoma. The impact
of WT1 gene expression on the clinical outcome of this
cancer was not demonstrated by previous studies [16,31].
The explanation for the discrepancy is not clear in the
present time. However, the influence of genetic back-
ground could be one of responsible factors. Further study
with larger sample size would be worthwhile to address
this issue. These observations support the hypothesis that
WT1 plays a role as an oncogene in this type of ovarian
cancer, as has been demonstrated in leukemia and breast
cancer [32].
Neither the quantitative level nor the intensity of WT1
expression were found to be related to overall or recur-
rence-free survival. By contrast, Garg et al. studied quanti-
tative WT1 gene transcripts by competitive reverse
transcription polymerase chain reaction in acute leukemia
and found that accurate quantification of WT1 gene tran-
scripts in both acute myeloid leukemia and acute lym-
phoblastic leukemia patients at presentation was an
important prognostic pretreatment characteristic and a
useful predictive marker of leukemia relapse [30].
In several previous studies, the prognostic value of other
clinicopathologic variables (i.e. FIGO stage, histologic
type, histologic grade, and primary residual tumor) has
been shown [33,34], but the present study was unable to
show any association with stage, histologic grade, or size
of residual tumor. This difference might be explained by
the fact that we enrolled only cases with advanced stage;
at this stage earlier prognostic indicators might no longer
have prognostic significance. The small number of stage
IV patients also resulted in a wide confidence interval for
the univariate hazard ratio for overall survival, extending
upwards to over 2, so our data were not incompatible with
FIGO stage as a prognostic indicator. Response to chemo-
therapy was a highly significant predictor of survival
among our patients.
Conclusion
Our study suggests that expression of WT1 gene may be
indicative of an unfavorable prognosis in patients with
advanced serous epithelial ovarian carcinoma.
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